• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, October 31, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

A combined approach to treating metastatic melanoma

Bioengineer by Bioengineer
May 30, 2016
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Oncologists at the Fred Hutchinson Cancer Research Center have successfully treated a patient with metastatic melanoma by combining two different types of immunotherapy. Cassian Yee and colleagues describe their approach in a paper, "Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient," that will be published online May 30 in The Journal of Experimental Medicine.

Melanoma is the most serious form of skin cancer, accounting for the vast majority of skin cancer deaths when it spreads, or metastasizes, to other organs in the body. Many approaches to treating metastatic melanoma are based on boosting the immune system's ability to target and destroy the tumor. One strategy is to isolate pure populations of the patient's T cells that can target the melanoma and then transfer them back into the patient. Another approach is to treat patients with ipilimumab, an antibody that activates the patient's existing antitumor T cells by blocking the function of a protein called CTLA4. On their own, both treatments can slow the progression of metastatic melanoma, but they are rarely able to send the disease into complete remission. Yee and colleagues wondered whether combining the two approaches might be more effective.

The researchers tested their idea on a 53-year-old patient with multiple metastases who had previously shown little response to either T cell transfers or ipilimumab treatment. The patient now received an infusion of his own antitumor T cells that had been treated with an immune signaling protein, called interleukin-21, that promotes T cell survival. Immediately afterward, the patient received a dose of ipilimumab. Within weeks, the patient's tumors began to shrink, and they eventually disappeared completely. Yee and colleagues report that, over five years later, the patient remains disease free.

The researchers found that their combined approach boosted the number of antitumor T cells circulating in the patient's blood in both the short and long term. Moreover, the enhanced immune response induced by this treatment allowed the patient to develop new types of T cells that attacked the melanoma in additional ways, a phenomenon known as epitope spreading.

"Combining CTLA4 blockade with the transfer of well-characterized, robust antitumor T cells represents an encouraging strategy to enhance the activity of the adoptively transferred T cells and induce antitumor responses," says Yee, who now works at The University of Texas MD Anderson Cancer Center in Houston. "This strategy may hold broad promise for ipilimumab-resistant melanomas."

###

Chapuis et al. 2016. J. Exp. Med. http://dx.doi.org/10.1084/jem.20152021

About The Journal of Experimental Medicine The Journal of Experimental Medicine (JEM) is published by The Rockefeller University Press. All editorial decisions on submitted manuscripts are made by research-active scientists in conjunction with our in-house scientific editors. JEM provides free online access to many article types immediately, with complete archival content freely available online since the journal's inception. Authors retain copyright of their published works, and third parties may reuse the content for non-commercial purposes under a Creative Commons license. For more information, please visit jem.org. Follow us on Twitter at @JExpMed and @RockUPress.

Media Contact

Ben Short
[email protected]
212-327-7053
@RockUPress

http://www.rupress.org/

The post A combined approach to treating metastatic melanoma appeared first on Scienmag.

Share29Tweet8Share2ShareShareShare2

Related Posts

Hypoxia Fuels Metastasis in Synovial Sarcoma

October 31, 2025

New Triple Therapy Shows Promise for Liver Cancer

October 31, 2025

Global Burden of GI Cancers in Youth

October 31, 2025

Axicabtagene Ciloleucel Outperforms Conventional First-Line Therapy

October 31, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1293 shares
    Share 516 Tweet 323
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    312 shares
    Share 125 Tweet 78
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    202 shares
    Share 81 Tweet 51
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    136 shares
    Share 54 Tweet 34

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

New Tool Assesses Family Resources for Dementia Care

Tanshinone IIA Halts Heat-Driven Growth in Liver Cancer

Hypoxia Fuels Metastasis in Synovial Sarcoma

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 67 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.